RxDoctor Payments Data

Vanessa Lucarella, MD

Cardiovascular Disease · Clearwater, FLNPI 1427048081

Payments from drug & device makers

$109,085in general payments, 2019–2025

Across 154 payments — averaging $708.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim International GmbH$70K
  • Merck$19K
  • Boehringer Ingelheim Pharma GmbH & Co.kg$18K
  • Boston Scientific$199
  • Amgen$196
  • Novartis$159
  • plus $416 from 8 others

What the payments were for

  • Food & beverage$971100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$109,085 in reported general payments places this provider in the 90th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$1,397,396
Medicare patients
1,944
Services billed
8,884

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban367$438,943
XareltoRivaroxaban201$251,669
Repatha SureclickEvolocumab96$103,817
EntrestoSacubitril/Valsartan72$68,954
MultaqDronedarone Hcl22$23,078
Praluent PenAlirocumab16$19,913
Metoprolol Succinate1,404$19,408
BrilintaTicagrelor20$18,757
Rosuvastatin Calcium1,323$15,293
JardianceEmpagliflozin13$14,544
OzempicSemaglutide12$13,548
Atorvastatin Calcium1,151$10,654
Amlodipine Besylate1,058$7,334
Nebivolol Hcl91$6,926
Flecainide Acetate214$6,645

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$80$438,943367 claims
Johnson & JohnsonXarelto$98$251,669201 claims
NovartisEntresto$159$68,95472 claims
Sanofi-aventis U.S. LLCMultaq$61$23,07822 claims
AstraZenecaBrilinta$54$18,75720 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Clearwater

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →